Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.50 |
| ▸ | BDKRB1 | P46663 | 12/20 | 0.45 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15862086 | 0.91 | KDM4A (0.44) | EPHX2NR1H4KDM4ANOTUM | |
| SCHEMBL1495902 | 0.88 | EPHX2 (0.64) | EPHX2NR1H4BDKRB1KDM4A | |
| SCHEMBL23832914 | 0.86 | EPHX2 (0.49) | EPHX2NR1H4BDKRB1KDM4A | |
| SCHEMBL30193009 | 0.86 | EPHX2 (0.49) | EPHX2NR1H4BDKRB1KDM4A | |
| SCHEMBL1495846 | 0.85 | EPHX2 (0.49) | EPHX2KDM4ANOTUM | |
| SCHEMBL30739196 | 0.85 | EPHX2 (0.48) | EPHX2NR1H4KDM4A | |
| SCHEMBL507345 | 0.85 | EPHX2 (0.48) | EPHX2NR1H4BDKRB1KDM4A | |
| SCHEMBL15729681 | 0.85 | EPHX2 (0.54) | EPHX2NR1H4KDM4A | |
| SCHEMBL2441663 | 0.84 | NOTUM (0.48) | KDM4ANOTUM | |
| SCHEMBL21711922 | 0.84 | SERPINE1 (0.41) | EPHX2NR1H4BDKRB1KDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3886854-A1 | PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THEREOF | Nuvation Bio Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| US-11034669-B2 | Pyrrole and pyrazole compounds and methods of use thereof | NUVATION BIO INC. (BM) | 2021-06-15 | — | — | US | disclosed |
| US-11034669-B2 | Pyrrole and pyrazole compounds and methods of use thereof | NUVATION BIO INC. (BM) | 2021-06-15 | — | — | US | disclosed |
| US-20200239433-A1 | PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2020-07-30 | — | — | US | disclosed |
| US-20200239433-A1 | PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2020-07-30 | — | — | US | disclosed |
| WO-2020113094-A1 | PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THEREOF | NUVATION BIO INC. (US) | 2020-06-04 | — | — | WO | disclosed |
| EP-1781661-B1 | VASOPRESSIN V1A ANTAGONISTS | VANTIA LTD (GB) | 2017-06-07 | — | — | EP | disclosed |
| US-8202858-B2 | Vasopressin V1a antagonists | VANTIA LIMITED (GB) | 2012-06-19 | — | — | US | disclosed |
| US-8202858-B2 | Vasopressin V1a antagonists | VANTIA LIMITED (GB) | 2012-06-19 | — | — | US | disclosed |
| US-8202858-B2 | Vasopressin V1a antagonists | VANTIA LIMITED (GB) | 2012-06-19 | — | — | US | disclosed |
| EP-1660501-A2 | PIPERAZINES AS OXYTOCIN AGONISTS | FERRING B.V. (NL) | 2006-05-31 | — | — | EP | disclosed |
| EP-1632494-A1 | Vasopressin v1a antagonists | FERRING B.V. (NL) | 2006-03-08 | — | — | EP | disclosed |
| WO-2006021213-A2 | VASOPRESSIN V1A ANTAGONISTS | FERRING B.V. (NL) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006021213-A2 | VASOPRESSIN V1A ANTAGONISTS | FERRING B.V. (NL) | 2006-03-02 | — | — | WO | disclosed |
| EP-1592693-A1 | BENZAMIDE DERIVATIVES AS OXYTOCIN AGONISTS AND VASOPRESSIN ANTAGONISTS | Ferring B.V. (NL) | 2005-11-09 | — | — | EP | disclosed |
| WO-2005023812-A2 | PIPERAZINES AS OXYTOCIN AGONISTS | FERRING B.V. (NL) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005023812-A2 | PIPERAZINES AS OXYTOCIN AGONISTS | FERRING B.V. (NL) | 2005-03-17 | — | — | WO | disclosed |
| EP-1512687-A1 | Piperazines as oxytocin agonists | FERRING B.V. (NL) | 2005-03-09 | — | — | EP | disclosed |
| WO-2004072083-A1 | BENZAMIDE DERIVATIVES AS OXYTOCIN AGONISTS AND VASOPRESSIN ANTAGONISTS | FERRING B.V. (NL) | 2004-08-26 | — | — | WO | disclosed |
| EP-1449844-A1 | benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING B.V. (NL) | 2004-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239433-A1 | PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THEREOF | NCOA3, NCOA1, NR3C1 | EPHX2 3882/4885NR1H4 69/4885BDKRB1 1906/4885 |
| US-11034669-B2 | Pyrrole and pyrazole compounds and methods of use thereof | NCOA3, NCOA1, NR3C1 | EPHX2 3882/4885NR1H4 69/4885BDKRB1 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.